Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insomnia01:27

Insomnia

111
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
111
Management of Insomnia01:19

Management of Insomnia

292
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
292
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

210
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
210
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

288
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
288
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

373
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
373
Insufficient Sleep and Sleep Deprivation01:13

Insufficient Sleep and Sleep Deprivation

189
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can We Monitor and Enhance Glymphatic Clearance During Sleep?

Sleep·2026
Same author

Novel TMS-derived metrics enable machine learning classification of major depressive disorder.

NPP - digital psychiatry and neuroscience·2026
Same author

Insomnia disorder and cerebrospinal fluid markers of dementia.

Journal of Alzheimer's disease : JAD·2025
Same author

Insomnia's psychiatric health connection through shared cellular programs.

Sleep·2025
Same author

Effects of acute sleep deprivation and recovery sleep on cognitive performance in depressed individuals.

Journal of psychiatric research·2025
Same author

An open, fully-processed data resource for studying mood and sleep variability in the developing brain.

bioRxiv : the preprint server for biology·2025
Same journal

Nighttime light exposure is associated with metabolic dysfunction in schizophrenia: A cross-sectional analysis of the LENS study.

Sleep·2026
Same journal

Sleep Need Outcompetes Preparation: Reframing Sleep Initiation Through Naturalistic Behaviour.

Sleep·2026
Same journal

The Quest for Automated Pediatric Sleep Scoring: Are We There Yet?

Sleep·2026
Same journal

Sex Differences in the Sleep Architecture and Sleep-Disordered Breathing in C57BL/6 J Mice.

Sleep·2026
Same journal

Differential Effects of Prenatal Depression and Anxiety on Infant Sleep: Dual-Pathway Mechanisms Involving the HPA Axis and the Gut-Brain Axis.

Sleep·2026
Same journal

Metabolic Syndrome and Obstructive Sleep Apnea: Two Sides of the Same Coin.

Sleep·2026
See all related articles

Related Experiment Video

Updated: Aug 3, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.1K

Does insomnia treatment prevent depression?

Elaine M Boland1,2, Jennifer R Goldschmied1, Philip R Gehrman1,2

  • 1Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Sleep
|April 8, 2023
PubMed
Summary
This summary is machine-generated.

Treating insomnia with cognitive behavioral treatment for insomnia (CBT-I) may help prevent major depressive disorder (MDD) onset. Evidence suggests CBT-I reduces depression risk, though more research is needed.

Keywords:
Cognitive Behavioral TherapyDepressionInsomnia

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

751
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.5K

Related Experiment Videos

Last Updated: Aug 3, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.1K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

751
The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.5K

Area of Science:

  • Mental Health
  • Neuroscience
  • Public Health

Background:

  • Major depressive disorder (MDD) rates are rising globally, exacerbated by the COVID-19 pandemic.
  • Insomnia is a known risk factor for depression and is linked to increased severity and poorer treatment outcomes.
  • Targeting insomnia treatment is a logical strategy for preventing new and recurrent episodes of MDD.

Approach:

  • This systematic review evaluated existing evidence on the preventive effects of insomnia treatment on depression onset.
  • A comprehensive database search identified 186 studies, with six meeting the inclusion criteria.
  • All included studies focused on cognitive behavioral treatment for insomnia (CBT-I), often delivered digitally.

Key Points:

  • Four of the six studies reported significantly lower rates of MDD onset in participants receiving CBT-I compared to control groups.
  • The remaining two studies did not find significant preventive effects in primary analyses, but secondary analyses indicated potential benefits.
  • Methodological heterogeneity across studies (sample selection, outcomes, follow-up) limits definitive conclusions.

Conclusions:

  • The current evidence suggests a trend towards insomnia treatment, specifically CBT-I, reducing the risk of developing MDD.
  • Further rigorous research is warranted to confirm these preventive effects and establish optimal treatment protocols.
  • Digital delivery of CBT-I shows promise as a scalable intervention for MDD prevention.